[
  {
    "ts": null,
    "headline": "India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal",
    "summary": "Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after its unit signed a licensing deal with U.S. peer AbbVie for its early-stage blood cancer treatment. ...",
    "url": "https://finnhub.io/api/news?id=aba7909ff1771c2a9050f82d012d644b80221bba7f52c348339302cdb7fde02a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752191771,
      "headline": "India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal",
      "id": 135866039,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after its unit signed a licensing deal with U.S. peer AbbVie for its early-stage blood cancer treatment. ...",
      "url": "https://finnhub.io/api/news?id=aba7909ff1771c2a9050f82d012d644b80221bba7f52c348339302cdb7fde02a"
    }
  },
  {
    "ts": null,
    "headline": "India's Glenmark Pharma soars 10% to record high on AbbVie cancer licensing deal",
    "summary": "Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after its unit signed a licensing deal with U.S. peer AbbVie for its early-stage blood cancer treatment. ...",
    "url": "https://finnhub.io/api/news?id=ceedbe8b4a0c26dc23982dd827ba08e34f20b1f84a72b95cba0ea1cd690fa6a4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752191771,
      "headline": "India's Glenmark Pharma soars 10% to record high on AbbVie cancer licensing deal",
      "id": 135865300,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after its unit signed a licensing deal with U.S. peer AbbVie for its early-stage blood cancer treatment. ...",
      "url": "https://finnhub.io/api/news?id=ceedbe8b4a0c26dc23982dd827ba08e34f20b1f84a72b95cba0ea1cd690fa6a4"
    }
  },
  {
    "ts": null,
    "headline": "Glenmark Pharma jumps on unit's cancer licensing deal with AbbVie",
    "summary": "Shares of Glenmark Pharmaceuticals jumped 10% in early trade on Friday, a day after a unit of the Indian drugmaker signed an exclusive licensing deal with U.S. peer AbbVie for its cancer treatment. ...",
    "url": "https://finnhub.io/api/news?id=eb436279d254f005115c2bc5d81809e799710e4fd5d011ab7ed6d00b7416033e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752191771,
      "headline": "Glenmark Pharma jumps on unit's cancer licensing deal with AbbVie",
      "id": 135864693,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Shares of Glenmark Pharmaceuticals jumped 10% in early trade on Friday, a day after a unit of the Indian drugmaker signed an exclusive licensing deal with U.S. peer AbbVie for its cancer treatment. ...",
      "url": "https://finnhub.io/api/news?id=eb436279d254f005115c2bc5d81809e799710e4fd5d011ab7ed6d00b7416033e"
    }
  },
  {
    "ts": null,
    "headline": "Glenmark Pharma jumps on unit's cancer treatment licensing deal with AbbVie",
    "summary": "Shares of Glenmark Pharmaceuticalsjumped 10% in early trade on Friday, a day after aunit of the Indian drugmaker signed an exclusive licensing dealwith U.S. peer AbbVie for its cancer...",
    "url": "https://finnhub.io/api/news?id=a7ed9cf10ad0dee871ba0b659b83b6f853c92b79e3024669f7752a955301d697",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752191349,
      "headline": "Glenmark Pharma jumps on unit's cancer treatment licensing deal with AbbVie",
      "id": 135866042,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Shares of Glenmark Pharmaceuticalsjumped 10% in early trade on Friday, a day after aunit of the Indian drugmaker signed an exclusive licensing dealwith U.S. peer AbbVie for its cancer...",
      "url": "https://finnhub.io/api/news?id=a7ed9cf10ad0dee871ba0b659b83b6f853c92b79e3024669f7752a955301d697"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Laps the Stock Market: Here's Why",
    "summary": "AbbVie (ABBV) closed the most recent trading day at $195, moving +2.3% from the previous trading session.",
    "url": "https://finnhub.io/api/news?id=17bacb398fd352bc18cb228fe84b3f73e91329c2bcd16a4667003d052d6c9ccf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752183902,
      "headline": "AbbVie (ABBV) Laps the Stock Market: Here's Why",
      "id": 135865043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) closed the most recent trading day at $195, moving +2.3% from the previous trading session.",
      "url": "https://finnhub.io/api/news?id=17bacb398fd352bc18cb228fe84b3f73e91329c2bcd16a4667003d052d6c9ccf"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Stunned: AbbVie Drops $700M on a Little-Known Indian Cancer Drug",
    "summary": "A high-stakes bet on a biotech underdog could reshape the global cancer treatment landscape--and boost Glenmark's profile overnight.",
    "url": "https://finnhub.io/api/news?id=02961ba3d92ec738a48fa6f1e07535d5d0376be5fc03317fa1702a09d2eb722c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752177188,
      "headline": "Wall Street Stunned: AbbVie Drops $700M on a Little-Known Indian Cancer Drug",
      "id": 135865044,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "A high-stakes bet on a biotech underdog could reshape the global cancer treatment landscape--and boost Glenmark's profile overnight.",
      "url": "https://finnhub.io/api/news?id=02961ba3d92ec738a48fa6f1e07535d5d0376be5fc03317fa1702a09d2eb722c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV): A Bull Case Theory",
    "summary": "We came across a bullish thesis on AbbVie Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $185.62 as of June 30th. ABBV’s trailing and forward P/E were 79.32 and 15.27 respectively according to Yahoo Finance. AbbVie Inc. (ABBV), a global biopharmaceutical leader, specializes […]",
    "url": "https://finnhub.io/api/news?id=23845318854e577d4c6cffb2c461ba310fec232926471784771ce9e778482418",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752170658,
      "headline": "AbbVie Inc. (ABBV): A Bull Case Theory",
      "id": 135865046,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on AbbVie Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $185.62 as of June 30th. ABBV’s trailing and forward P/E were 79.32 and 15.27 respectively according to Yahoo Finance. AbbVie Inc. (ABBV), a global biopharmaceutical leader, specializes […]",
      "url": "https://finnhub.io/api/news?id=23845318854e577d4c6cffb2c461ba310fec232926471784771ce9e778482418"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=518ff224a8d16dc343a25bba72c75fd2601f745e6e2e5a2d8c198b0f877eea0d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752165120,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 135949315,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=518ff224a8d16dc343a25bba72c75fd2601f745e6e2e5a2d8c198b0f877eea0d"
    }
  },
  {
    "ts": null,
    "headline": "Tesla robotaxi, AbbVie licenses Glenmark cancer drug, McDonald's",
    "summary": "Yahoo Finance anchor Julie Hyman examines some of the top headlines on Wall Street on Thursday, July 10 in this episode of Market Minute. Tesla (TSLA) CEO Elon Musk says the company plans to expand its robotaxi rollout to San Francisco in the coming months. Glenmark (GLENMARK.NS, GLENMARK.BO) is set to license its cancer drug to AbbVie (ABBV), sending shares of both companies higher. McDonald's (MCD) was upgraded to Buy from Neutral by Goldman Sachs analysts, saying the fast-food restaurant is well-positioned to serve value-seeking consumers. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=91200d2a3611047ad8b5142d54f49ddc82668025ea7a4397e4cee7cd2629f11f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752164671,
      "headline": "Tesla robotaxi, AbbVie licenses Glenmark cancer drug, McDonald's",
      "id": 135864612,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Yahoo Finance anchor Julie Hyman examines some of the top headlines on Wall Street on Thursday, July 10 in this episode of Market Minute. Tesla (TSLA) CEO Elon Musk says the company plans to expand its robotaxi rollout to San Francisco in the coming months. Glenmark (GLENMARK.NS, GLENMARK.BO) is set to license its cancer drug to AbbVie (ABBV), sending shares of both companies higher. McDonald's (MCD) was upgraded to Buy from Neutral by Goldman Sachs analysts, saying the fast-food restaurant is well-positioned to serve value-seeking consumers. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=91200d2a3611047ad8b5142d54f49ddc82668025ea7a4397e4cee7cd2629f11f"
    }
  },
  {
    "ts": null,
    "headline": "Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody",
    "summary": "IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases.",
    "url": "https://finnhub.io/api/news?id=56998702b59f6c38b68d64da072550cdc651401f6a77b901d9e1abe3ce0fbae1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752160980,
      "headline": "Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody",
      "id": 135855743,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases.",
      "url": "https://finnhub.io/api/news?id=56998702b59f6c38b68d64da072550cdc651401f6a77b901d9e1abe3ce0fbae1"
    }
  },
  {
    "ts": null,
    "headline": "India's Glenmark Pharma unit, AbbVie sign exclusive licensing pact",
    "summary": "(Reuters) -India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have signed an exclusive licensing agreement for IGI's cancer treatment, adding to the U.S. firm's oncology portfolio.  Under the agreement, AbbVie will get exclusive rights to develop, manufacture and commercialize IGI's ISB 2001 in North America, Europe, Japan and Greater China.",
    "url": "https://finnhub.io/api/news?id=d75527d1e5ccd36d5235aa1c4c455fda4f762b146f29e70728858133b4f881b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752147828,
      "headline": "India's Glenmark Pharma unit, AbbVie sign exclusive licensing pact",
      "id": 135855744,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "(Reuters) -India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have signed an exclusive licensing agreement for IGI's cancer treatment, adding to the U.S. firm's oncology portfolio.  Under the agreement, AbbVie will get exclusive rights to develop, manufacture and commercialize IGI's ISB 2001 in North America, Europe, Japan and Greater China.",
      "url": "https://finnhub.io/api/news?id=d75527d1e5ccd36d5235aa1c4c455fda4f762b146f29e70728858133b4f881b1"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody",
    "summary": "AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases.",
    "url": "https://finnhub.io/api/news?id=904bca242503f9b1dbe8e78aca55c3f3331c9466a01fa686c9b3b55d0e3773b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752147000,
      "headline": "AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody",
      "id": 135855745,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases.",
      "url": "https://finnhub.io/api/news?id=904bca242503f9b1dbe8e78aca55c3f3331c9466a01fa686c9b3b55d0e3773b5"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to pay $700M for trispecific drug from Ichnos Glenmark",
    "summary": "The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and autoimmune conditions, too.",
    "url": "https://finnhub.io/api/news?id=e4f75233b90534b600febc6a5f9bacc881d07055b780b8c2f3c4f40a96c3b50f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752145920,
      "headline": "AbbVie to pay $700M for trispecific drug from Ichnos Glenmark",
      "id": 135855746,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and autoimmune conditions, too.",
      "url": "https://finnhub.io/api/news?id=e4f75233b90534b600febc6a5f9bacc881d07055b780b8c2f3c4f40a96c3b50f"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025",
    "summary": "Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN stock is upgraded to buy.",
    "url": "https://finnhub.io/api/news?id=2495b4aff067e964fa9334b784dd6c51873da2d471928bb2c9a40098efee24f3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752138900,
      "headline": "Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025",
      "id": 135851366,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1336356688/image_1336356688.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN stock is upgraded to buy.",
      "url": "https://finnhub.io/api/news?id=2495b4aff067e964fa9334b784dd6c51873da2d471928bb2c9a40098efee24f3"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie and Ichnos Glenmark Innovation Announce Exclusive Global Licensing Agreement for ISB 2001, a First-In-Class CD38xBCMAxCD3 Trispecific Antibody",
    "summary": "AbbVie and IGI Therapeutics SA announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT®? protein platform, for oncology and...",
    "url": "https://finnhub.io/api/news?id=7b6b51da1d85020420000d55e02b015fc5483d41871b44e7143125a22d991f2f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752137460,
      "headline": "AbbVie and Ichnos Glenmark Innovation Announce Exclusive Global Licensing Agreement for ISB 2001, a First-In-Class CD38xBCMAxCD3 Trispecific Antibody",
      "id": 135850593,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie and IGI Therapeutics SA announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT®? protein platform, for oncology and...",
      "url": "https://finnhub.io/api/news?id=7b6b51da1d85020420000d55e02b015fc5483d41871b44e7143125a22d991f2f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie in Immuno-Oncology Licensing Pact with IGI Therapeutics",
    "summary": "By Colin Kellaher AbbVie has struck an immuno-oncology licensing agreement with IGI Therapeutics that is potentially worth more than $1.9 billion to the clinical-stage biotechnology company. ...",
    "url": "https://finnhub.io/api/news?id=b8c0b36e775f9988e239da51924183e702a18cb61558add4f66bd0f7892e2b1c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752136936,
      "headline": "AbbVie in Immuno-Oncology Licensing Pact with IGI Therapeutics",
      "id": 135850362,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "By Colin Kellaher AbbVie has struck an immuno-oncology licensing agreement with IGI Therapeutics that is potentially worth more than $1.9 billion to the clinical-stage biotechnology company. ...",
      "url": "https://finnhub.io/api/news?id=b8c0b36e775f9988e239da51924183e702a18cb61558add4f66bd0f7892e2b1c"
    }
  },
  {
    "ts": null,
    "headline": "Glenmark Pharma says Ichnos Glenmark Innovation (IGI), AbbVie announce exclusive global licensing agreement",
    "summary": "Glenmark Pharmaceuticals Ltd: Ichnos Glenmark Innovation and AbbVie announce exclusive global licensing agreement Licensing agreement for ISB 2001 IGI will receive an upfront payment of $700...",
    "url": "https://finnhub.io/api/news?id=ae863f47c98151d5d60124e83054b169adebfc85654650c094c6ea5e2dc2da34",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752133341,
      "headline": "Glenmark Pharma says Ichnos Glenmark Innovation (IGI), AbbVie announce exclusive global licensing agreement",
      "id": 135848840,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Glenmark Pharmaceuticals Ltd: Ichnos Glenmark Innovation and AbbVie announce exclusive global licensing agreement Licensing agreement for ISB 2001 IGI will receive an upfront payment of $700...",
      "url": "https://finnhub.io/api/news?id=ae863f47c98151d5d60124e83054b169adebfc85654650c094c6ea5e2dc2da34"
    }
  }
]